ReviewFrontiers in pharmacology2022

Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering?

Andrea Zanello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.